Summary
Ruxolitinib is a Janus kinase (JAK) 2 inhibitor that is an effective therapeutic agent for primary myelofibrosis (PMF), which helps significantly to reduce constitutional symptoms and spleen size. However, this drug has significant immunomodulatory effects that may lead to various opportunistic infections. Reactivation of tuberculosis and certain viral infections have been well documented. Although a few reports of patients with pulmonary cryptosporidiosis on ruxolitinib exist, an extensive literature review shows only one previously reported case of cryptococcal meningoencephalitis in an immunocompetent patient on ruxolitinib, with a history of avian exposure. Here we report another extremely rare incidence of cryptococcal meningitis in a fully immunocompetent male patient on ruxolitinib, with no history of contact with birds. Although this is an approved and effective therapy for PMF, careful evaluation, screening, and prophylaxis in susceptible individuals should be considered before starting therapy.
References
Dioverti MV, Saleh AOM, Tande AJ. Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature. Infect Dis. 2017;50(5):381–7. https://doi.org/10.1080/23744235.2017.1390248.
McLornan DP, Khan AA, Harrison CN. Immunological consequences of JAK inhibition: friend or foe? Curr Hematol Malig Rep. 2015;10:370–9.
Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.
Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of Ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.
Hirano A, Yamasaki M, Saito N, et al. Pulmonary cryptosporidiosis in a Ruxolitinib treated patient with primary myelofibrosis. Respir Med Case Rep. 2017;22:87–90.
Chen CC, Chen YY, Huang CE. Cryptococcal meningoencephalitis associated with the long-term use of Ruxolitinib. Ann Hematol. 2016;95(2):361–2.
Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with Ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143(5):1478–9.
Seminario-Vidal L, Cantrell W, Elewski BE. Pulmonary cryptococcosis in the setting of Tofacitinib therapy for psoriasis. J Drugs Dermatol. 2015;14(8):901–2.
Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor Ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122:1192–202.
Parampalli Yajnanarayana S, Stubig T, Cornez I, et al. JAK1/ 2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169:824–33.
Schonberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75:2187–99.
Islam R, Yellu MR, Rafiullah, et al. Low-dose Ruxolitinib for improving leukopaenia and reducing recurrent infections associated with myelofibrosis. Bmj Case Rep. 2013;2013(1) https://doi.org/10.1136/bcr-2013-010068.
Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122:3843–4.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
A. Chakrabarti and N. Sood declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Chakrabarti, A., Sood, N. Cryptococcal meningitis in an immunocompetent patient with primary myelofibrosis on long-term ruxolitinib: report of a rare case and review of literature. memo 11, 348–350 (2018). https://doi.org/10.1007/s12254-018-0435-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-018-0435-8